[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"stock-detail-EPRX":3,"homepage-market-summary":30,"stock-news-EPRX":172},{"ticker":4,"date":5,"profile":6,"dividend":9,"quote":14},"EPRX","2026-10-02",{"name":7,"exchange":8,"sector":9,"industry":10,"description":11,"ceo":9,"employees":12,"headquarters":9,"founded":9,"is_fund":13,"issuer":9,"category":9},"Eupraxia Pharmaceuticals Inc. Common Stock","Nasdaq",null,"Common Stock","Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.","49",false,{"close":15,"open":16,"high":17,"low":18,"prev_close":19,"change":20,"percent_change":21,"volume":22,"transactions":23,"vwap":24,"high_52w":25,"low_52w":26,"avg_volume_52w":27,"range_52w_percent":28,"record_count":29},7.24,8,8.09,7.19,7.83,-0.59,-7.54,1710851.74422,15867,7.5609,9.32,5.25,288289.623781972,48.9,626,{"status":31,"indices":32,"watchlist":76,"sectors":98,"benchmarks":154},"success",[33,41,48,55,62,69],{"symbol":34,"name":35,"price":36,"change":37,"pct_change":38,"is_up":39,"sparkline":40,"date":5},"SPX","S&P 500",7722.72,56.27,0.73,true,"0.0,5.0 2.3,8.0 4.6,10.4 6.9,13.4 9.3,9.1 11.6,11.5 13.9,13.8 16.2,16.0 18.5,10.3 20.8,9.5 23.2,2.0 25.5,2.0 27.8,5.9 30.1,6.0 32.4,3.4 34.7,7.3 37.1,8.2 39.4,9.4 41.7,8.5 44.0,4.8",{"symbol":42,"name":43,"price":44,"change":45,"pct_change":46,"is_up":39,"sparkline":47,"date":5},"NDX","NASDAQ 100",30807.93,306.37,1,"0.0,11.5 2.3,11.7 4.6,12.4 6.9,14.8 9.3,12.8 11.6,14.6 13.9,16.0 16.2,15.9 18.5,12.2 20.8,10.7 23.2,4.4 25.5,2.6 27.8,4.5 30.1,4.5 32.4,3.5 34.7,6.0 37.1,5.5 39.4,5.0 41.7,4.3 44.0,2.0",{"symbol":49,"name":50,"price":51,"change":52,"pct_change":53,"is_up":39,"sparkline":54,"date":5},"DJI","DOW JONES",51177,250,0.49,"0.0,2.0 2.3,5.5 4.6,7.8 6.9,9.5 9.3,6.7 11.6,7.5 13.9,9.4 16.2,12.9 18.5,11.1 20.8,11.7 23.2,9.6 25.5,10.7 27.8,12.6 30.1,13.5 32.4,10.8 34.7,12.8 37.1,13.5 39.4,16.0 41.7,15.9 44.0,14.5",{"symbol":56,"name":57,"price":58,"change":59,"pct_change":60,"is_up":39,"sparkline":61,"date":5},"COMP","NASDAQ Composite",27190.86,319.27,1.19,"0.0,10.2 2.3,11.1 4.6,13.0 6.9,14.9 9.3,12.1 11.6,13.7 13.9,16.0 16.2,16.0 18.5,11.1 20.8,10.0 23.2,3.4 25.5,2.0 27.8,5.4 30.1,5.4 32.4,3.9 34.7,6.7 37.1,6.9 39.4,6.2 41.7,6.1 44.0,2.6",{"symbol":63,"name":64,"price":65,"change":66,"pct_change":67,"is_up":39,"sparkline":68,"date":5},"RUT","RUSSELL 2000",2815.2,25,0.9,"0.0,2.0 2.3,3.0 4.6,6.1 6.9,8.4 9.3,7.5 11.6,8.8 13.9,10.4 16.2,11.3 18.5,10.2 20.8,11.2 23.2,10.1 25.5,8.8 27.8,12.9 30.1,13.1 32.4,12.8 34.7,14.4 37.1,15.1 39.4,16.0 41.7,15.1 44.0,13.2",{"symbol":70,"name":71,"price":72,"change":73,"pct_change":74,"is_up":13,"sparkline":75,"date":5},"VIX","CBOE VIX",15.31,-1.08,-6.59,"0.0,14.8 2.3,10.2 4.6,7.3 6.9,2.0 9.3,9.7 11.6,4.9 13.9,4.5 16.2,2.5 18.5,11.3 20.8,13.7 23.2,13.5 25.5,16.0 27.8,12.3 30.1,10.4 32.4,13.5 34.7,8.8 37.1,8.9 39.4,7.8 41.7,7.6 44.0,11.8",[77,84,91],{"symbol":78,"name":79,"price":80,"change":81,"pct_change":82,"is_up":39,"sparkline":83,"date":5},"NVDA","NVIDIA Corp",233.95,3.09,1.34,"0.0,16.0 7.3,15.3 14.7,9.6 22.0,12.1 29.3,10.3 36.7,6.6 44.0,2.0",{"symbol":85,"name":86,"price":87,"change":88,"pct_change":89,"is_up":39,"sparkline":90,"date":5},"AAPL","Apple Inc",333.69,3.37,1.02,"0.0,8.2 7.3,2.0 14.7,5.2 22.0,16.0 29.3,11.7 36.7,14.9 44.0,10.9",{"symbol":92,"name":93,"price":94,"change":95,"pct_change":96,"is_up":39,"sparkline":97,"date":5},"TSLA","Tesla Inc",370.59,16.48,4.65,"0.0,2.0 7.3,5.3 14.7,13.4 22.0,16.0 29.3,14.9 36.7,15.3 44.0,6.1",[99,104,109,114,119,124,129,134,139,144,149],{"name":100,"etf":101,"change":102,"price":103,"is_up":39},"Technology","XLK",1.01,199.81,{"name":105,"etf":106,"change":107,"price":108,"is_up":39},"Financials","XLF",0.06,53.49,{"name":110,"etf":111,"change":112,"price":113,"is_up":13},"Healthcare","XLV",-0.01,166.18,{"name":115,"etf":116,"change":117,"price":118,"is_up":39},"Consumer Cycl","XLY",1.13,110.04,{"name":120,"etf":121,"change":122,"price":123,"is_up":39},"Consumer Staples","XLP",0.25,80.53,{"name":125,"etf":126,"change":127,"price":128,"is_up":39},"Energy","XLE",0.4,62.95,{"name":130,"etf":131,"change":132,"price":133,"is_up":39},"Industrials","XLI",0.78,169.95,{"name":135,"etf":136,"change":137,"price":138,"is_up":39},"Materials","XLB",0.66,48.86,{"name":140,"etf":141,"change":142,"price":143,"is_up":39},"Real Estate","XLRE",0.32,40.81,{"name":145,"etf":146,"change":147,"price":148,"is_up":39},"Utilities","XLU",0.38,39.83,{"name":150,"etf":151,"change":152,"price":153,"is_up":39},"Comm Services","XLC",0.35,110.32,[155,160,164,168],{"ticker":156,"name":157,"price":158,"change":159,"is_up":39},"SPY","SPDR S&P 500 ETF",769.64,0.74,{"ticker":161,"name":162,"price":163,"change":89,"is_up":39},"QQQ","Invesco QQQ Trust",749.58,{"ticker":165,"name":166,"price":167,"change":53,"is_up":39},"DIA","SPDR Dow Jones ETF",511.1,{"ticker":169,"name":170,"price":171,"change":67,"is_up":39},"IWM","iShares Russell 2000",281.52,{"ticker":4,"count":173,"articles":174},20,[175,181,187,193,199,204,210,216,221,226,232,237,241,246,250,254,259,264,268,272],{"title":176,"link":177,"pubDate":178,"description":179,"source":180},"Fifty-two weeks after one dose, 9 of 14 patients with an esophageal disease remained in remission. - stocktitan.net","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMivwFBVV95cUxOMHhkS19pRHkwM19jWWF2ZG9XT2JnS0plbnB4UGEtcGlndi1sV0hES0dMQ0gxVk5kOTJIbW1pQ1ZKeldXcnpqRXdhRDZrVDZYeUl0UGwwTHowTkpKSG4ybFF5bWpKcGhHSHAtd2ZBa1lpUFFVbHNCdEZxMVhGTTZEWXYwWVI1aS1ZVThKTm1GX001aElUY180M2NETl9Nd3Zya2ZKOVRNZ3hXMkJDcjF0SEpESEVET1Vhajg2VzJfTQ?oc=5","Wed, 30 Sep 2026 12:00:00 GMT","Fifty-two weeks after one dose, 9 of 14 patients with an esophageal disease remained in remission. stocktitan.net","stocktitan.net",{"title":182,"link":183,"pubDate":184,"description":185,"source":186},"Eupraxia Pharmaceuticals (TSX:EPRX) Stock Drops 13.86% After 52-Week RESOLVE Data as Phase 2b Readout Moves to December - kalkine.ca","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi4wFBVV95cUxPYllLd1RCUXNVSzYwZEJoZW5hSXBYMVJPQlk0R3hGejBCVmtDME5qQUU3QWV6WjdVaW1INEtsaE0wVzNNNmtSYnVCZldISzh1TEx0UExyM1FBSncweUFZd1hmMU9wblVNWnQ0dzJoUEhCa28yQV8wdFVVRXhuT2pKbklRendzVEFvQkJOb3ZDdDNfWHhoaWh4Zk5RbENUV3paZ05ybE1IdmdxQ1QtX1ZOa1ZyX255Y2pFREM0bWw4STBKWnNBTXFpZU8xTkRTbDl0dkJtY0JHVXVwSG84N3oxYmI1QQ?oc=5","Fri, 02 Oct 2026 10:38:00 GMT","Eupraxia Pharmaceuticals (TSX:EPRX) Stock Drops 13.86% After 52-Week RESOLVE Data as Phase 2b Readout Moves to December kalkine.ca","kalkine.ca",{"title":188,"link":189,"pubDate":190,"description":191,"source":192},"(EPRX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMixwFBVV95cUxONWgwMVp6MzdtWTBQeHY1YWh4ZEdLRHVOWXFJcG9rS05RQklfalFmS3Q5bkwwT205YjE2MVlXUnBYV25sa1RIRHU4d2lUVjRGZnpaMWNtb1piN1lsMDZrUGk2VFpiTVdxc0lNZW1FeDN1N1d6WHhoWm9sLVVyQk9pT2pFNEJsVjZNd0k0NVFKd1I2cEJXTjFVb2RzeWVNUzR0bElUdVpwRmJyUVlzT2RzcU9NblBNNWppeVN4OXA2QWVFY044Nzd3?oc=5","Sun, 27 Sep 2026 16:50:02 GMT","(EPRX) Movement Within Algorithmic Entry Frameworks Stock Traders Daily","Stock Traders Daily",{"title":194,"link":195,"pubDate":196,"description":197,"source":198},"Stifel reiterates Buy rating on Eupraxia stock ahead of trial data - Investing.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMixAFBVV95cUxOdl9FcVB2NlJscC15M3E5THJXWVNMZzhRT2lPVFltWDl6R1I5WlRLNVMyaGpSbXRMRjdrZEw1SHBPN2ZEc09qOVJyRHZjbUJDSndRQ1FJeC1tQkIzSFBKT045VXZNNEFZandZQ2hlV1dGNkhZc1lIcmpfNVJzaHZydmVCZmd5aURMSXoyOFQ1SXpsMWdsSHFRVHlxeVQyeEgyOFZ5am5KUjBOZmdnb2xmOW54Z2JzdUhveG9KMXotM2loUkUw?oc=5","Thu, 24 Sep 2026 10:24:51 GMT","Stifel reiterates Buy rating on Eupraxia stock ahead of trial data Investing.com","Investing.com",{"title":200,"link":201,"pubDate":202,"description":203,"source":180},"After one dose, Eupraxia (EPRX) reports patients still in remission at 52 weeks. - stocktitan.net","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwgFBVV95cUxQQmRSdXJKNWYwM21zLU9VbU5CQ1NEMzRlazI3MkR6WFI1WTJMcjhBaVRVY1czRU9GeW1FVXNBNVY5S0laSDR4S3BjdnQwc3dEblpTempXaHkwSEdLbHRiYjRsMVJjMVJjMVBMSXFPamw4SlVaQVFNcUhJZUh2dkVNQWE5N2V4YVkxNlJnM01fYzdCdkpfbkxrellzbjdwSVFaUTd3cVFXMS1qckxBQnE0SFlCU2FMLWxPbjcycERIckNtdw?oc=5","Wed, 30 Sep 2026 12:05:08 GMT","After one dose, Eupraxia (EPRX) reports patients still in remission at 52 weeks. stocktitan.net",{"title":205,"link":206,"pubDate":207,"description":208,"source":209},"Stock Market sell-off: These eight Nifty 50 stocks are at or near 52-week lows - CNBC TV18 - LinkedIn","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMitAFBVV95cUxPNm5LV2oxSGR3UUI3M3BWcmgwa1o3UkpSOVYxdWZuZG1wdmdzTjFJYW1OUDNMNzZXdWVyTV9RcmFCZXJ3UmthYmczR1FtZThoVW1GMjhkc1c4UF9nYmpDR1FjLVdrbXM5dDZrRlBHSmFnMEhYVjFjcVpKelpoa0J5NHplVHg3OV9sWTVNT1hTR29Cc1VzaHA1RExiN3p1X3N5S0dna1JpU25OYXhZQkhYOExLcWk?oc=5","Mon, 28 Sep 2026 08:05:16 GMT","Stock Market sell-off: These eight Nifty 50 stocks are at or near 52-week lows - CNBC TV18 LinkedIn","LinkedIn",{"title":211,"link":212,"pubDate":213,"description":214,"source":215},"Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients - marketscreener.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi1wFBVV95cUxNWVJnalJQQVlHMU9aQ0NpNGhZemQ2aDVXLThKbGZYY3o1dEpKVVpjMThtMFBNckhXc3Mxb3NyQVhwdDRFZWtsazNlMmlacU80aGplNWY3S3pQTGJ6YllReUZndFpkZ21pV0w1QThkalR0YzhMa0hVS19VYU5qTTU3a05FVU4tamhacXNaOGRoQlRKd1BRTnROcGUtZjdaRHU0Si0yZ1htd3pfVzh2cGhva1FndzVkZ245aGNMbk5ZaGNDWWtycXRoaWJfeEdlOWFGTnFkVkUwWQ?oc=5","Wed, 30 Sep 2026 16:28:21 GMT","Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients marketscreener.com","marketscreener.com",{"title":217,"link":218,"pubDate":219,"description":220,"source":198},"Wedbush initiates Eupraxia Pharmaceuticals stock with Outperform rating - Investing.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiywFBVV95cUxPb2xmRDNQLVdPdXZ5TGR3d0Y0eFIzRHVmVGdGbEd2TkZmOXkwWDlEV192V05mTVUzNnVyVlY4TFIzNFBEeUFYYkhmNXdZb2tyX1RENTFEN3FBczU3U1Q1bktsT0xTcVNRWlFiVzlBTUhmY0I2cHloNUZuWEpXV29udWo1WmRVUGRCOFR6WjdCX0FXeWtYc1I1MWxJM3BqX3BGcmVZMWprS2Y1Y1UySVRCS1lxVktNYmQxa0VISDZUSV8wMVhCR2lVT3Jvcw?oc=5","Thu, 24 Sep 2026 07:00:00 GMT","Wedbush initiates Eupraxia Pharmaceuticals stock with Outperform rating Investing.com",{"title":222,"link":223,"pubDate":224,"description":225,"source":186},"Eupraxia Pharmaceuticals (TSX:EPRX) Stock Slips 5.13%: RESOLVE Trial Execution, Diffusphere Formulation Pacing, and Pre-Commercial Valuation Scrutinized - kalkine.ca","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiiwJBVV95cUxQanE3S0xweExkQ3QxOEZ2T2xacE9DMnpOMkhiTld3MEdqVmhpd2tzY1FUQTROckRlVlJ2aXBqSmhIWS0xRndUNTFjNHdmUU81VS1Ta25iWnRaclZJblhsVVAtNDZKcF8ybk9KaDJaMFdKbGhXenpYaTVVRmp5ZmpEM0c5ZjdsaGNuMTVDN2N0VnpmUFBadzIzNVJxd0ZDVlA4b3ZKbHlraXh1cEU2ZWFUZFVSRmZzSkRHQlJrbW1qeWRkMF9LZWtBdkZiVlY3VHRLZ0syZ1dGbE9YLUp1TEROc1dDNmhBXzR3d0RxOEotMUw5VGFvalU5dk15d1VaY1gxeVpiejVhbXNmZ1E?oc=5","Thu, 24 Sep 2026 13:16:00 GMT","Eupraxia Pharmaceuticals (TSX:EPRX) Stock Slips 5.13%: RESOLVE Trial Execution, Diffusphere Formulation Pacing, and Pre-Commercial Valuation Scrutinized kalkine.ca",{"title":227,"link":228,"pubDate":229,"description":230,"source":231},"Wainwright reiterates Eupraxia stock rating on positive trial data By Investing.com - Investing.com Nigeria","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMixgFBVV95cUxPLTVoVng0T0RSckZUVnV6MzlIOUstaWczQjZfd2xCN1lmTW91WEhTcEg3YTh0RU50MmxyZ1JXMGl0NkRUMHU4djZDWF8yN1BvajRNRnJMTDNSWTQteFFkd1pNbWRLOUFrX0hubGZ5Y0RFZHpJWVRnWmNnOWVkaEV0Z3FZMk55UG96VnpXWFhTbUJJVlZQNl94VFdBZVZjaUdYS0QwLWZjbzl3dUIxM3FSUG9kQTdyYkxWSDFZWlc2MXZmUkhRU1E?oc=5","Thu, 01 Oct 2026 13:23:55 GMT","Wainwright reiterates Eupraxia stock rating on positive trial data By Investing.com Investing.com Nigeria","Investing.com Nigeria",{"title":233,"link":234,"pubDate":235,"description":236,"source":186},"Eupraxia Pharmaceuticals (TSX:EPRX) Gains Momentum as Durable EoE Data Strengthens Investor Optimism - kalkine.ca","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMizAFBVV95cUxPNmZwWGVkOU8ycmtldVRacEFiejlpczZNaDdQNi1zeUJUaWdDT3dKQTNIUUFRNHV6OVBUUXBEZTNzX0RUQzlLc1FBczFvVGJQVGxPRkVxbFVGMnNCeTFBejdJZmJLODlLQUZrR1dkblAycW1BYW5sYWFzeW9JVzJoM2U1bEd4dEMzckhIWUxmR3U5NUZXTElGcFRweDVfaHlrSFRlYmZfSzRzZVJyMGxIbWdCcFhsTDcxRk80MkpjZkUtckN0T3FhLUhuX00?oc=5","Thu, 01 Oct 2026 07:32:00 GMT","Eupraxia Pharmaceuticals (TSX:EPRX) Gains Momentum as Durable EoE Data Strengthens Investor Optimism kalkine.ca",{"title":238,"link":239,"pubDate":224,"description":240,"source":186},"Custom Health Holdings (TSX:CHLT) Stock Drops 5.45%: Spencer Health Integration Pacing, Convertible Debt Overhang, and Digital Pharmacy Margins Scrutinized - kalkine.ca","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMijwJBVV95cUxQOGxWN29TbVdpSWgwTTM0YjhpQV81NXZXUzRpS1dKNzdUMXdTZ3NjYTBQcW11Y0ZGMFE0N0RBTXRyUktXeGJGdkJ2UG5WTWNMbE45TkwtT2I3bm1fSS0zdG9sd0JPbTRMSGNEZllBTFR5WWdJYjRyYnBBUmdmSlZvQXIwc3dzWVJVT3BuUlBIUjkzY0JpQVppa3dNeE5fTXhmVGJxSUc4ZU9UU0ZPVy10LTZ4d21ZLWRUd2hPM0JXbnlNMTNfVEk0VjF0bkRfQTdOWV9XSjdVaFB1OVJNZ1NKQ2FCWG5EWHBWVGpySVBGVmVfY2VnaTBxblFia1YzeEp3ZWRDRWdCbXlxa0ZvUjJ3?oc=5","Custom Health Holdings (TSX:CHLT) Stock Drops 5.45%: Spencer Health Integration Pacing, Convertible Debt Overhang, and Digital Pharmacy Margins Scrutinized kalkine.ca",{"title":242,"link":243,"pubDate":244,"description":245,"source":186},"Why Is COSCIENS Biopharma Stock Down 5.41%? Key Drivers and What Investors Are Watching (TSX:CSCI) - kalkine.ca","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMixgFBVV95cUxQRkVqTG9KYk1BTlZkWkFvV0NHLUJOck9HR0pTN25kVnRGRGJjMkdOUHpEMzdURlhyX3RGNk03RW54MGx1aEFaUkhaV3JRY05tQVFkb0pUUk1CcEVjY2lQd204Q0FVeHIzOHQyQ3JPTHJOUVVwVjBHZVczbVQ1WjBPczJXYzdKd2hRLVZ6eDBWMTl5VC1wWE9taFU3UGkzQWlmUTFSdFhYWFR6cjBWNi1vVUlDZEVLMEVKcEhPODhfNGJkYzJBeVE?oc=5","Fri, 02 Oct 2026 10:47:00 GMT","Why Is COSCIENS Biopharma Stock Down 5.41%? Key Drivers and What Investors Are Watching (TSX:CSCI) kalkine.ca",{"title":247,"link":248,"pubDate":184,"description":249,"source":186},"Jushi Holdings Stock Rebounds 13.89% After Rescheduling Hearing Stay Triggered Sharp Pullback (CN:JUSH) - kalkine.ca","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMizgFBVV95cUxQQV9RR2NwYUo0emVnbnR5WEljaHo4UGxEOENyMjhYTFlvOVRINm4tNnZ1T2VwS1U5a3N5UDc5N2FMN0xMdWV4aGRNQ2ROYk5Ua3h0Y3hkWXpuLU5YRTJrd3dOYmZwTEdaamFHZkRKeUpvY2NteGdtOFVhNEtoOGJFS1RMU1hZRGlDTDVnM2x2bGptLVp6MzR4bHdTcHZKc1N6WGtlZUxNeWZBenZyMjVlTGwxTTFnQUsyQTJzMlVQYjhNQUJ1aWZ4eEJocC16dw?oc=5","Jushi Holdings Stock Rebounds 13.89% After Rescheduling Hearing Stay Triggered Sharp Pullback (CN:JUSH) kalkine.ca",{"title":251,"link":252,"pubDate":184,"description":253,"source":186},"Covalon Technologies Stock Rises 8.68% to New Highs as Record Quarter and AVA Showcase Lift Sentiment (TSXV:COV) - kalkine.ca","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi2gFBVV95cUxQLUtPdjVsT25EWXViUmt1TFR0UEpGdUpVS05IUjJzcDQwVVNGeFdGaU8wZVlVc3FoNmRWcGZ4bWQ4clVHUVhYbTI1dkRqTzFiQVBsd0VObGVmLWRnUzJjSFZCXzNKRUp5VDdwbVAyWWdiQlhINFlOU1I1akpWZFNPTWRROGo1bG9oRmk3bmh5MXlXb01ja3BTcWxfZHZNUXYzazJzZ0oxTjRYUWhjUzZkYldlZHowVUVVbU1ueUJYOFdENDdySkIyMWFuUUtTQm5pMVU1eTg0Zm4tUQ?oc=5","Covalon Technologies Stock Rises 8.68% to New Highs as Record Quarter and AVA Showcase Lift Sentiment (TSXV:COV) kalkine.ca",{"title":255,"link":256,"pubDate":257,"description":258,"source":186},"Cardiol Therapeutics Inc. Class A (TSX:CRDL) Slides -5.91% as Investors Reassess Near-Term Catalysts and Risk - kalkine.ca","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi0wFBVV95cUxQcGF3WDctRDQ1bk9lN2x3YXRZZE9ubjB6TEM2QVF4RXY5T05NV09VTkpwMVVhSzhCcHdtdmF5a3RVM3VQeXp4SS02NDlnYUFNZnp6TEFhdnl3ZkZYbEZpTGlLd29CRXZpWXN0akwzS3pOWjlaSW5IYUhXVG5vVGVkX0czeUlmSjZ2WFRSd01oWDQyWURZYkN5V0J5b1hEMm02UENiaDB4TlE0YmZlOXA5NzN6TUpOVmhCbVgzN2Z1WnhzZ0ZqNDlCelFneVphaWNFT2Vn?oc=5","Fri, 02 Oct 2026 11:11:00 GMT","Cardiol Therapeutics Inc. Class A (TSX:CRDL) Slides -5.91% as Investors Reassess Near-Term Catalysts and Risk kalkine.ca",{"title":260,"link":261,"pubDate":262,"description":263,"source":186},"Arch Biopartners, Inc. (TSXV:ARCH) Slides -6.74% as Investors Reassess Near-Term Catalysts and Risk - kalkine.ca","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMixAFBVV95cUxPenJiUXdrNWtwLUVWUUtteVdLT3R0bnJLb3FBSzFtU09nZk84N2h4Z1NxX1k5WGpsTklzX3JxbUdBdkVGSFpYVk5PN2dWaUFQcjh6d1N6M29BRUtlbjFzc2haRTdIRmtzVFp0bUlxYzZ1S1lOd2xhOWNRVmR2aEtvdWNZb1M2by1PN0JCQUx3QzVVYWhOR3NkRlVNQ0RpcFd6UlNFUVhHMmxPb2F1ZlNKb1BEMDF6RmRHbGl0amhkVU5kQlFr?oc=5","Fri, 02 Oct 2026 11:15:00 GMT","Arch Biopartners, Inc. (TSXV:ARCH) Slides -6.74% as Investors Reassess Near-Term Catalysts and Risk kalkine.ca",{"title":265,"link":266,"pubDate":184,"description":267,"source":186},"Devonian Health Group (TSXV:GSD) Stock Falls 8.38% as Investors Track NYSE American Listing Plan - kalkine.ca","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMixAFBVV95cUxOeFRYT2JlYkFJamJJSWRxY0dhWHV6VE1VU2lyOS1rZFV4cXNNUktLQjV6YjlNbTZrYkVNNG81SUJCejROVTV1Q3dMVy1qLUFNOXlhdEtycVdfMlRIUWlBQWszQU55YWt1aTQ1MVM1ZjhpZGNudHpKcTBqdmRFZnVYa1A4VHJ1eTgzUmpIbXZtb2s3TDRaMTAxcWlYSGpNbzJlQThNSGktc2FzaXVDMWlOOVdmSmlPOW1Rb2pxODNTVERFZlB4?oc=5","Devonian Health Group (TSXV:GSD) Stock Falls 8.38% as Investors Track NYSE American Listing Plan kalkine.ca",{"title":269,"link":270,"pubDate":184,"description":271,"source":186},"HLS Therapeutics (TSX:HLS) Stock Falls 7.38% Despite Expanded Share Buyback - kalkine.ca","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiqAFBVV95cUxNWEtNYjZYMnE2R21jYzVhcWlWNU9SWkxPVHpXS09DYzdObjBMMDlmTkkzX2oxQnVtZERfaGtGeFpPWV9SQ1ViZURXdWZYX0FUUlRHcFUyWmYtdjVzN0xUNTYwWkdQTzBhOEd4MktSRkRkcnhfQ2VFbmw2d1NEWldSd1Z0cFkyTHIxSV9XYnpjUzRyNXByUjRiME1lMU9QeHpUZ1VMOXBIcmM?oc=5","HLS Therapeutics (TSX:HLS) Stock Falls 7.38% Despite Expanded Share Buyback kalkine.ca",{"title":273,"link":274,"pubDate":262,"description":275,"source":186},"Decibel Cannabis Company Inc. (TSXV:DB) Jumps 3.05%: Why Investors Are Watching This Stock After the 1 October 2026 Move - kalkine.ca","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi4gFBVV95cUxOaUpWVWxYT1k2eDE5WXlDWEh6Q1BPX2hFTGNleUVweGhtYlU3Y1NNOGNaaDBLcHZ6VmhHN2tFZ0ZIR052d3U3UkxvOHh6b1RnM2hiaEhtV1BGYkNqdlJaeUY4X3Q2dE12UzBhZzBHWmNDNW9kSnc1OW1LUHZZOERQUUhFSXFMTXlhR1J4MEFsLUQwRTlWVENDbVhWa0R0WHFrWnM5NmJaWm51SHVUWloyTGZsRHoyc2l0ZVhoZWF0d3pZZmtVc1FNNHdsTkFFZmc0cGNzeVdVNFA0YUszc2FvakNB?oc=5","Decibel Cannabis Company Inc. (TSXV:DB) Jumps 3.05%: Why Investors Are Watching This Stock After the 1 October 2026 Move kalkine.ca"]